Dianthus Therapeutics
DNTHDianthus Therapeutics is advancing a pipeline of precision monoclonal antibodies to selectively inhibit the classical complement pathway, a key driver of autoimmune diseases. The company's lead candidate, DNTH103, is in Phase 1 clinical development for myasthenia gravis and other IgG-mediated autoimmune conditions. Dianthus aims to develop best-in-class therapies with improved convenience and safety profiles compared to existing complement inhibitors. The company leverages its expertise in complement biology to target diseases with high unmet medical need.
DNTH · Stock Price
Historical price data
AI Company Overview
Dianthus Therapeutics is advancing a pipeline of precision monoclonal antibodies to selectively inhibit the classical complement pathway, a key driver of autoimmune diseases. The company's lead candidate, DNTH103, is in Phase 1 clinical development for myasthenia gravis and other IgG-mediated autoimmune conditions. Dianthus aims to develop best-in-class therapies with improved convenience and safety profiles compared to existing complement inhibitors. The company leverages its expertise in complement biology to target diseases with high unmet medical need.
Technology Platform
Platform for developing selective monoclonal antibodies targeting specific components of the classical complement pathway, with initial focus on complement component 1s (C1s) inhibition.
Opportunities
Risk Factors
Competitive Landscape
Faces competition from established complement inhibitors (Alexion/AstraZeneca's C5 inhibitors) and emerging therapies targeting various points in the complement cascade. Differentiation strategy focuses on selective C1s inhibition and subcutaneous administration.